Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
January 26, 2021 16:00 ET | Source: Arcellx, Inc. Arcellx, Inc. Gaithersburg, Maryland, UNITED STATES
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the appointment of Rami Elghandour as Chairman of the Board and Chief Executive Officer, effective Jan. 22, 2021. Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role of Chief Technical Officer.
“I’m thrilled to join Arcellx and honored to lead the company as it advances its transformative cancer and autoimmune therapies,” said Rami Elghandour. “The results from Arcellx’s Phase I study in multiple myeloma validate the company’s proprietary technology and demonstrate the potential for a best-in-class therapy for many patients in ne